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Abstract 
Background/Aims:  Spontaneous acute exacerbation of chronic hepatitis B virus (HBV) 
infection occasionally occurs in its natural history, sometimes leading rapidly to fatal hepatic 
failure. We compared the effects of lamivudine (LAM) with those of entecavir (ETV) treat-
ments in acute exacerbation of chronic hepatitis B with 500 IU/L or higher alanine ami-
notransferase (ALT) levels. 
Methods:  Thirty-four patients with acute exacerbation were consecutively treated with 
LAM /ETV. Their clinical improvements were compared. 
Results: Among LAM-treated and ETV-treated patients, none showed a reduction of <1 log 
IU/mL in HBV DNA after 1 or 3 months of treatment. Initial virological response, defined as a 
reduction of 4 log IU/mL in HBV DNA at 6 months, with LAM and ETV, respectively, was 
83.3% and 100%. One LAM patient developed hepatic encephalopathy, but all patients in both 
groups survived. Twelve months after treatment, 41.6% of 24 LAM group patients switched to 
another drug or added adefovir to their treatment due to the emergence of LAM-resistant 
mutants. On the other hand, patients receiving ETV did not need to change drugs.  
Conclusions: ETV appears to be as effective as LAM in the treatment of patients with acute 
exacerbation of chronic hepatitis B. Clinicians should carefully start to treat these patients as 
soon as possible. 
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INTRODUCTION 
Chronic hepatitis B infection is associated with 
the development of hepatocellular carcinoma [1]. In-
fection with hepatitis B virus (HBV) also leads to wide 
a  spectrum  of  liver  injury,  including  acute, 
self-limited infection, fulminant hepatitis, and chronic 
hepatitis with progression to cirrhosis and liver fail-
ure,  as  well  as  to  an  asymptomatic  chronic  carrier 
state [2, 3].  
Reactivation of hepatitis B is a well-characterized 
syndrome marked by the abrupt reappearance or rise 
of HBV DNA in the serum of a patient with previ-
ously inactivated or resolved HBV infection [4]. Reac-
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tivation  is  often  spontaneous,  but  can  also  be  trig-
gered by cancer chemotherapy and immune suppres-
sion. Spontaneous acute exacerbation of chronic hep-
atitis B infection is seen with a cumulative probability 
of 15-37% after 4 years of follow-up [5]. Prognosis is 
generally  poor  in  HBV  carriers  with  spontaneous 
acute  exacerbation  together  with  high  alanine  ami-
notransferase (ALT) levels, jaundice, and liver failure 
[4,  6,  7].  This  condition  has  been  defined  as 
acute-on-chronic  liver  failure  according  to  a  recent 
Asia-Pacific  consensus  recommendation  [8].  Acute 
exacerbation occasionally leads to a critical scenario, 
meaning  that  clinicians  need  to  treat  this  condition 
immediately. 
Lamivudine (LAM) is a reverse-transcriptase in-
hibitor  of  viral  DNA  polymerase  with  an  excellent 
profile of safety and tolerability, causing inhibition of 
viral  replication,  and  it  is  approved  for  antiviral 
treatment  of  hepatitis  B  patients  [9,  10].  LAM  sup-
presses serum HBV DNA values in up to 98% of pa-
tients within a median period of 4 weeks, leading to 
aminotransferase normalization, increased hepatitis B 
e  antigen  (HBeAg)  seroconversion  rate,  and  im-
provement of histological parameters [11, 12]. A study 
from Taiwan showed that LAM had a survival benefit 
and was effective for patients with baseline bilirubin 
levels below 20 mg/dL [7]. 
 Entecavir (ETV), a deoxyguanosine analogue, is 
a potent and selective inhibitor of HBV replication; its 
in vitro potency is 100- to 1,000-fold greater than that 
of LAM, and it has a selectivity index (concentration 
of  drug  reducing  the  viable  cell  number  by  50% 
[CC50]/concentration of drug reducing viral replica-
tion by 50% [EC50]) of ~8,000 [13, 14]. At present, the 
Japanese national health insurance system approves 
ETV as the first-line therapy for chronic hepatitis B, 
although some patients are treated with standard in-
terferon-alfa.  ETV  is  a  nucleoside  analogue  (NUC) 
belonging to a new subgroup, cyclopentane [15], and 
it has been shown to be highly effective in suppress-
ing  HBV  replication  to  an  undetectable  level  and 
normalizing  ALT,  although  NUCs  do  not  eradicate 
the virus. ETV develops less resistance than LAM. 
We undertook a retrospective study to compare 
the efficacy of LAM with that of ETV in the reduction 
of HBV DNA levels and associated improvement in 
disease severity and biochemical recovery in patients 
with  acute  exacerbation  together  with  higher  ALT 
levels due to HBV reactivation. 
MATERIALS AND METHODS 
Patients 
 A  retrospective  analysis  of  LAM/ETV-treated 
chronic hepatitis B patients at Chiba University Hos-
pital and Numazu City Hospital, Japan, between May 
2003 and December 2009 was performed. The inclu-
sion criteria were: acute exacerbation of chronic hep-
atitis B characterized by an elevation of ALT level ≥ 
500  IU/L  along  with  HBV  DNA  ≥  4.5  log  IU/mL 
presenting in a patient with diagnosed chronic liver 
disease. The exclusion criteria were: acute hepatitis B, 
superinfection with other viruses (hepatitis E, A, D, or 
C), other causes of chronic liver failure [16, 17], coex-
istent  hepatocellular  carcinoma,  portal  thrombosis, 
coexistent  renal  impairment,  pregnancy,  coinfection 
with  human  immunodeficiency  virus  (HIV),  or  pa-
tients who  had received a previous course of NUC 
treatment. This retrospective study protocol conforms 
to  the  ethical  guidelines  of  the  1975  Declaration  of 
Helsinki as reflected in a priori approval by the Ethics 
Committee of Chiba University, Graduate School of 
Medicine [18]. 
Baseline assessment of patients 
Retrospectively  collected  data  included  patient 
demographics, clinical findings, all laboratory varia-
bles including virological tests and abdominal ultra-
sound.  HBsAg,  HBeAg,  anti-HBe  antibody  and  im-
munoglobulin M (IgM) anti-HBc antibody were de-
termined  by  ELISA  (Abbott,  Chicago,  IL,  USA)  or 
CLEIA (Fujirebio, Tokyo, Japan) [19]. HBV genotype 
was determined from patients’ sera by ELISA (Insti-
tute  of  Immunology,  Tokyo,  Japan)  as  reported  by 
Usuda et al [20]. HBV DNA was measured by Roche 
AmplicorTM  PCR  assay  (detection  limits:  2.6  log 
IU/mL; Roche Diagnostics, Tokyo, Japan). 
Definitions 
Primary antiviral treatment failure was defined 
as a reduction of < 1 log IU/mL in HBV DNA after 3 
months of therapy. Initial virological response (IVR) 
was defined as a reduction of ≥ 4 log IU/mL in HBV 
DNA after 6 months of therapy [21]. 
Follow-up 
Clinical  assessment  and  routine  investigations 
were done every 15 days or every month for at least 6 
months.  HBV  DNA  measurements  were  repeated 
monthly. 
Statistical analysis 
 Statistical  analyses  were  performed  using  Mi-
crosoft Excel 2010 for WindowsTM 7 and StatView 5 
(SAS Institute Inc, Cary,  NC). Continuous variables 
were  expressed  as  mean ±  standard  deviation  and 
were  compared  by  two-factor  analysis  of  variance 
(ANOVA) and two-way repeated measures ANOVA. 
Categorical variables were compared by Chi-square Int. J. Med. Sci. 2012, 9 
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test. Baseline was taken as the date when the first dose 
of  LAM/ETV  was  administered.  Statistical  signifi-
cance was considered at a P-value < 0.05. 
RESULTS 
Patients 
 Between May 2003 and December 2009, 34 pa-
tients with spontaneous acute exacerbation of chronic 
hepatitis B, with ALT levels ≥ 500 IU/mL and treated 
with LAM or ETV, were consecutively enrolled and 
retrospectively analyzed. 24 (70.5%) were treated with 
LAM at 100 mg daily and 10 (29.4%) were treated with 
ETV at 0.5 mg daily. All patients were followed for at 
least 6 months. Mean follow-up in the LAM and ETV 
groups was 55.5 ± 25.4 and 16.5 ± 9.9 months, respec-
tively. 
Baseline characteristics 
Baseline characteristics in the two patient groups 
were  similar  (Table  1).  Median  age  was  37  (21-73) 
years and 79.4% were men. One patient of the LAM 
group developed hepatic encephalopathy, but recov-
ered. All patients in both groups survived. At admis-
sion, the serological profile showed HBsAg positivity 
in all 34 (100%); 22 (64.7%) were HBeAg positive. The 
median HBV DNA  level  was 7.4 log IU/mL  in the 
LAM  group  and  7.9  log  IU/mL  in  the  ETV  group 
(Table 1). 
 
Table 1  Demographic, Clinical, and Laboratory Varia-
bles of Patients at Entry. 
Parameters  Total Pa-
tients (N=34) 
LAM (N=24)  ETV (N=10)  P-value 
Age (years)  37 (21-73)  37 (21-73)  39 (24-67)  NS 
Male (%)  27 (79.4)  18 (75)  9 (90)  NS 
Cirrhosis 
(+/-) 
2/32  2/22  0/10  NS 
ALT (IU/L)  986 
(523-2,450) 
995 
(523-2,450) 
1,046 
(523-2,140)  
NS 
T. Bil 
(mg/dL) 
2.0 (0.8-22.0)  2.4 (0.8-20.6)  1.6 (1.9-22.0)  NS 
PT (%)  83 (24-121)  81.5 (24-119)  83.6 (35-121)  NS 
HBeAg 
(+/-) 
22/12  18/6  4/6  NS 
HBV DNA 
(log IU/mL) 
7.6 (4.8-8.7)  7.4 (5.2-8.7)  7.9 (4.8-8.7)  NS 
LAM, lamivudine; ETV, entecavir; ALT, alanine aminotransferase; 
T. BIL, total bilirubin; PT, prothrombin time; NS, statistically not 
significant. 
 
Reduction in HBV DNA of total patients 
LAM  significantly  reduced  HBV  DNA  levels 
from baseline 7.24 log IU/mL to 3.27 log IU/mL at 1 
month (P < 0.001), to 2.21 log IU/mL at 3 months (P < 
0.001), and to 1.53 log IU/mL at 6 months (P < 0.001). 
ETV also significantly reduced HBV DNA levels from 
baseline 7.56 log IU/mL to 3.12 log IU/mL at 1 month 
(P < 0.001), to 2.14 log IU/mL at 3 months (P < 0.001), 
and to 1.77 log IU/mL at 6 months (P < 0.001). There 
were no differences in HBV DNA levels from baseline 
to 6 months between the two groups. None with pri-
mary antiviral treatment failure was identified in ei-
ther group. There were no significant differences in 
IVR between the two groups (Figure 1). 
Reduction in ALT levels of total patients 
LAM  significantly  reduced  ALT  levels  from 
baseline 1,130 IU/mL to 102 (P < 0.001) at 1 month, to 
28.6 (P < 0.001) at 3 months, and to 23.1 (P < 0.001) at 6 
months.  ETV  also  significantly  reduced  ALT  levels 
from  baseline  1,210  IU/mL  to  117  (P  <  0.001)  at  1 
month, to 25 (P < 0.001) at 3 months, and to 24.4 (P < 
0.001) at 6 months. There were no differences in ALT 
levels  from  baseline  to  6  months  between  the  two 
groups (Figure 2). 
 
 
Figure 1  Initial virological response (IVR). IVR was de-
fined as a reduction of ≥ 4 log IU/mL in HBV DNA after 6 
months of therapy [21]. 
 
 
 
Figure 2  Efficacy  of  lamivudine  and  entecavir  for  ALT 
levels. Lamivudine (N=24) vs. entecavir (N=10); data are 
shown as mean ± SD. 
 Int. J. Med. Sci. 2012, 9 
 
http://www.medsci.org 
30 
Reduction in HBV DNA of HBeAg-positive 
patients 
It has been demonstrated that the levels of HBV 
DNA  in  the  HBeAg-positive  phase  were  generally 
higher than those in the ant-HBe-positive phase [19, 
22].  HBeAg  positivity  is  also  associated  with  HBV 
viremia  and  increased  ALT  levels  in  HIV/HBV 
co-infected patients [23]. Next, we compared the re-
sponse to LAM or ETV in 18 or 4 HBeAg-positive pa-
tients,  respectively  (Table  2).  LAM  significantly  re-
duced HBV DNA levels from baseline 7.52 log IU/mL 
to 3.35 log IU/mL (P < 0.001) at 1 month, to 2.38 log 
IU/mL (P < 0.001) at 3 months, and to 1.55 log IU/mL 
(P < 0.001) at 6 months. ETV also significantly reduced 
HBV DNA levels from baseline 8.42 log IU/mL to 3.87 
log IU/mL (P < 0.001) at 1 month, to 2.90 log IU/mL 
(P < 0.001) at 3 months, and to 2.22 log IU/mL (P < 
0.001) at 6 months. There were no differences in HBV 
DNA levels from baseline to 6 months between the 
two groups. Primary antiviral treatment failure was 
not  observed  in  either  group.  Four  patients  in  the 
LAM group did not achieve IVR. 
 
Table 2  Demographic, Clinical, and Laboratory Varia-
bles of HBeAg-positive Patients at Entry. 
Parameters  Total Patients 
(N=22) 
LAM (N=18)  ETV (N=4)  P-value 
Age (years)  34.5 (21-51)  36.5 (21-51)  30 (24-33)  NS 
Male (%)  18 (81.8)  14 (77.7)  4 (100)  NS 
Cirrhosis (+/-) 1/21  1/17  0/4  NS 
ALT (IU/L)  1,030 
(523-2,450) 
1,990 
(523-2,450)  
1,363 
(980-1,620)  
NS 
T. Bil (mg/dL) 1.75 (0.8-20.6)  2.0 (0.8-20.6)  1.5 (1.0-18.7)  NS 
PT (%)  77 (24-119)  73.6 (24-119)  95.0 (44.1-113) NS 
HBeAg (+)  22  18  4   
HBV DNA 
(log IU/mL) 
7.6 (5.5- 8.8)  7.6 (5.5- 8.7)  8.6 (7.6- 8.7)  NS 
LAM, lamivudine; ETV, entecavir; ALT, alanine aminotransferase; 
T. BIL, total bilirubin; PT, prothrombin time; NS, statistically not 
significant. 
 
Reduction in ALT levels of HBeAg-positive 
patients 
LAM  significantly  reduced  ALT  levels  from 
baseline 1,150 IU/mL to 84 (P < 0.001) at 1 month, to 
27.5 (P < 0.001) at 3 months, and to 22.0 (P < 0.001) at 6 
months.  ETV  also  significantly  reduced  ALT  levels 
from baseline 1,460 IU/mL to 230 (P = 0.0038) at 1 
month, to 22.2 (P = 0.0016) at 3 months, and to 24.0 (P 
= 0.0016) at 6 months. At 1 month after treatment, the 
ALT levels of the LAM groups were lower than those 
of the ETV group (P < 0.0001) (Figure 3). During fol-
low-up periods, 10 and 1 sero-converters of HBeAg to 
anti-HBe antibody phase were seen in 18 LAM-treated 
and in 4 ETV-treated patients, respectively. 
 
 
Figure 3  Efficacy  of  lamivudine  and  entecavir  for  ALT 
levels in HBeAg-positive patients. Lamivudine (N=18) vs. 
entecavir (N=4); data are shown as mean ± SD. 
 
Safety 
No patient stopped taking medications. Twelve 
months after treatment, 10 of 24 patients (41.6%) in the 
LAM  group  switched  from  LAM  to  ETV  (n=4)  or 
added  adefovir  (n=6)  due  to  the  emergence  of 
LAM-resistant mutants. On the other hand, patients 
receiving ETV did not need to change their medica-
tion. 
DISCUSSION 
The present study compared the use of NUCs, 
LAM and ETV, for the treatment of acute exacerbation 
of chronic hepatitis B. The results clearly showed sig-
nificant  benefits  of  a  rapid  reduction  of  HBV  DNA 
levels, compared with untreated patients in a previ-
ous report [4].  
It was reported that ETV treatment is associated 
with increased short-term mortality in patients with 
severe acute exacerbation of chronic hepatitis B, but 
that it achieves better virological response in the long 
run [24]. We used LAM or ETV for patients with acute 
exacerbation  of  chronic  hepatitis  B  presenting  with 
ALT ≥ 500 IU/L in the present study. The effects of 
LAM on HBV DNA levels were the same as those of 
ETV (Figure 1). But the effects of LAM on ALT levels 
after  1  month  were  stronger  than  those  of  ETV  in 
HBeAg-positive  patients  (Figure  3).  In  spite  of  the 
limited  number  of  these  patients,  the  effects  were 
possibly  related  to  immunomodulating  activities  of 
LAM [25]. The patients’ prognoses were more favor-
able than in the previous report [4]. This might have Int. J. Med. Sci. 2012, 9 
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depended  on  the  fact  that,  in  the  present  study, 
treatment was begun as soon as possible, and some 
patients may have had a milder grade of acute exac-
erbation of chronic hepatitis B than those in the pre-
vious report [4]. We believe that patients with acute 
exacerbation  of  chronic  hepatitis  B  need  to  be  sub-
jected to treatment as promptly as possible. 
The major routes of HBV infection in our country 
have  been  mother-to-child  transmission  and  blood 
transfusion.  However,  cases  with  HBV  transmitted 
through  sexual  contact  are  increasing,  especially 
among HIV-1-seropositive patients [26]. One should 
bear in mind that knowledge about interactions be-
tween  ETV  and  anti-HIV  nucleoside  analogues  is 
limited [27]. Because long-term use of LAM induces 
LAM-resistant mutants [28], we can only use LAM for 
short-term treatment of patients with acute exacerba-
tion  of  chronic  hepatitis  B.  On  the  other  hand,  the 
present  study  also  revealed  that  patients  receiving 
ETV did not need to change drugs. 
Recently,  there  have  been  several  reports  that 
reactivation of HBV is a fatal complication following 
systemic chemotherapy or other immunosuppressive 
therapy  including  rituximab  and  steroid  therapies 
mainly in HBsAg-positive and  -negative lymphoma 
patients. It is important to enable early diagnosis of 
HBV  reactivation  as  well  as  initiation  of  antiviral 
therapy [29, 30]. 
In conclusion, ETV appears to be as effective as 
LAM in the treatment of patients with acute exacer-
bation of chronic hepatitis B. Clinicians should start to 
treat these patients with NUCs as soon as possible. 
ACKNOWLEDGEMENTS 
This work was supported by the Japan Science 
and Technology Agency, Ministry of Education, Cul-
ture, Sports, Science and Technology, Japan [21590829 
(TK), 21590828 (FI), and 21390225 (OY)], a grant from 
the  Japan  Society  of  Hepatology  (TK),  and  a  grant 
from  Chiba  University  Young  Research-Oriented 
Faculty Member Development Program in Bioscience 
Areas (TK). 
This work was partly presented at 21st Confer-
ence of the Asian Pacific Association for the Study of 
the Liver on 17 February 2011, Queen Sirkit National 
Convention Center, Bangkok, Thailand. 
ABBREVIATIONS 
ETV: Entecavir; HIV: Human immunodeficiency 
virus; IVR: Initial virological response; LAM: Lamiv-
udine; NUC: Nucleoside analogue. 
CONFLICT OF INTEREST 
The authors have declared that no conflict of in-
terest exists. 
REFERENCES 
1.  Di Bisceglie AM. Hepatitis B and Hepatocellular Carcinoma. 
Hepatology. 2009; 49 (5 Suppl): S56-S60. 
2.  Omata M, Ehata T, Yokosuka O, et al. Mutations in the precore 
region of hepatitis B virus DNA in patients with fulminant and 
severe hepatitis. N Engl J Med. 1991; 324: 1699-1704. 
3.  Liang TJ, Hasegawa K, Rimon N, et al. A hepatitis B virus mu-
tant associated with an epidemic of fulminant hepatitis. N Engl 
J Med. 1991; 324: 1705-1709. 
4.  Garg  H,  Sarin  SK,  Kumar  M,  et  al.  Tenofovir  improves  the 
outcome in patients with spontaneous reactivation of hepatitis 
B  presenting  as  acute-on-chronic  liver  failure.  Hepatology. 
2011; 53: 774-780. 
5.  Lok AS, Lai CL. Acute exacerbation in Chinese patients with 
chronic  hepatitis  B  virus  (HBV)  infection.  Incidence,  predis-
posing factors and etiology. J Hepatol. 1990; 10: 29-34. 
6.  Oketani M, Ido A, Tsubouchi H. Changing etiologies and out-
comes of acute liver failure: A perspective from Japan. J Gas-
troenterol Hepatol. 2011; 26 (Suppl 1): 65-71. 
7.  Chien RN, Lin CH, Liaw YF. The effect of lamivudine therapy 
in  hepatic  decompensation  during  acute  exacerbation  of 
chronic hepatitis B. J Hepatol. 2003; 38: 322-327. 
8.  Sarin SK, Kumar A, Almeida JA, et al. Acute-on-chronic liver 
failure: consensus recommendations of the Asian Pacific Asso-
ciation for the study of the liver (APASL). Hepatol Int. 2009; 3: 
269-282. 
9.  Dienstag JL, Perrillo R, Schiff ER, et al. A preliminary trial of 
lamivudine  for  chronic  hepatitis  B  infection.  N  Engl  J  Med. 
1999; 333: 1657-1661. 
10.  Lai CL, Chien RN, Leung NW, et al. A one-year trial of lamiv-
udine for chronic hepatitis B. Asia Hepatitis Lamivudine Study 
Group. N Engl J Med. 1998; 339: 61-68. 
11.  Dienstag JL, Schiff ER, Wright TL, et al. Lamivudine as initial 
treatment for chronic hepatitis B in the United States. N Engl J 
Med. 1999; 341: 1256-1263. 
12.  Potthoff A, Tillmann HL, Bara C, et al. Improved outcome of 
chronic hepatitis B after heart transplantation by long-term an-
tiviral therapy. J Viral Hepat. 2006; 13: 734-741. 
13.  Innaimo  SF,  Seifer  M,  Bisacchi  GS,  et  al.  Identification  of 
BMS-200475 as a potent and selective inhibitor of hepatitis B 
virus. Antimicrob Agents Chemother. 1997; 41: 1444-1448. 
14.  Ono SK, Kato N, Shiratori Y, et al. The polymerase L528M mu-
tation  cooperates  with  nucleotide  binding-site  mutations,  in-
creasing hepatitis B virus replication and drug resistance. J Clin 
Invest. 2001; 107: 449-455. 
15.  Yuen MF, Lai CL. Treatment of chronic hepatitis B: evolution 
over two decades. J Gastroenterol Hepatol. 2011; 26 (Suppl 1): 
S138-S143. 
16.  Kanda T, Yokosuka O, Ehata T, et al. Detection of GBV-C RNA 
in  patients  with  non-A-E  fulminant  hepatitis  by  re-
verse-transcription  polymerase  chain  reaction.  Hepatology. 
1997; 25: 1261-1265. 
17.  Kanda T, Yokosuka O, Ikeuchi T, et al. The role of TT virus 
infection  in  acute  viral  hepatitis.  Hepatology.  1999;  29: 
1905-1908. 
18.  Kamezaki  H,  Kanda  T,  Wu  S,  et  al.  Emergence  of 
entecavir-resistant  mutations  in  nucleos(t)ide-naïve  Japanese 
patients  infected  with  hepatitis  B  virus:  Virological  break-
through is also dependent on adherence to medication. Scand J 
Gastroenterol. 2011; 46: 1111-1117. Int. J. Med. Sci. 2012, 9 
 
http://www.medsci.org 
32 
19.  Wu S, Kanda T, Imazeki F, et al. Hepatitis B virus e antigen 
downregulates cytokine  production  in  human  hepatoma cell 
lines. Viral Immunol. 2010; 23: 467-476. 
20.  Usuda S, Okamoto H, Iwanari H, et al. Serological detection of 
hepatitis B virus genotypes by ELISA with monoclonal anti-
bodies to type-specific epitopes in the preS2-region product. J 
Virol Methods. 1999; 80: 97-112. 
21.  Gallego A, Sheldon J, Garcia-Samaniego J, et al. Evaluation of 
initial  virological  response  to  adefovir  and  development  of 
adefovir-resistant mutations in patients with chronic hepatitis 
B. J Viral Hepat. 2008; 15: 392-398. 
22.  Fujiwara K, Yokosuka O, Ehata T, et al. The two different states 
of  hepatitis  B  virus  DNA  in  asymptomatic  carriers: 
HBe-antigen-positive  versus  anti-HBe-positive  asymptomatic 
carriers. Dig Dis Sci. 1998; 43: 368-376. 
23.  Mendes-Correa MC, Pinho JR, Gomes-Gouvea MS, et al. Pre-
dictors of HBeAg status and hepatitis B viremia in HIV-infected 
patients with chronic hepatitis B in the HAART era in Brazil. 
BMC Infect Dis. 2011; 11: 247. 
24.  Wong  VW,  Wong  GL, Yiu  KK, et  al.  Entecavir  treatment in 
patients with severe acute exacerbation of chronic hepatitis B. J 
Hepatol. 2011; 54: 236-242. 
25.  Sarin  SK,  Sandhu  BS,  Sharma  BC,  et  al.  Beneficial  effects  of 
‘lamivudine  pulse’  therapy  in  HBeAg-positive  patients  with 
normal ALT. J Viral Hepat. 2004; 11: 552-558. 
26.  Fujisaki S, Yokomaku Y, Shiino T, et al. Outbreak of infections 
by hepatitis B virus genotype A and transmission of genetic 
drug resistance in patients coinfected with HIV-1 in Japan. J 
Clin Microbiol. 2011; 49: 1017-1024. 
27.  Lindh M, Uhnoo I, Blackberg J, et al. Treatment of chronic hep-
atitis  B  infection:  An  update  of  Swedish  recommendations. 
Scand J Infect Dis. 2008; 40: 436-450. 
28.  Seta  T,  Yokosuka  O,  Imazeki  F,  et  al.  Emergence  of  YMDD 
motif mutants of hepatitis B virus during lamivudine treatment 
of  immunocompetent  type  B hepatitis  patients.  J  Med  Virol. 
2000; 60: 8-16. 
29.  Kusumoto S, Tanaka Y, Ueda R, et al. Reactivation of hepatitis B 
virus  following  rituximab-plus-steroid  combination  chemo-
therapy. J Gastroenterol. 2011; 46: 9-16. 
30.  Yeo W, Johnson PJ. Diagnosis, prevention and management of 
hepatitis  B  virus  reactivation  during  anticancer  therapy. 
Hepatology. 2006; 43: 209-220.  